Drugs / Cellgram-LC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04689152 | Mar 2021 → Aug 2027 expected | alcoholic liver cirrhosis | Pharmicell Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05093881 | Aug 2021 → Aug 2026 overdue | alcoholic liver cirrhosis | Pharmicell Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellgram-LC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05093881 ↗ |
| Route | Other | “single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery” NCT04689152 ↗ |